News >

Predictive Factors Found for Treatment With FCO in CLL

Ariela Katz
Published: Friday, Jul 14, 2017

CLL
A mutation on the NOTCH1 gene was shown to be an independent predictive factor for the reduced efficacy of ofatumumab (Arzerra), a human monoclonal CD20 antibody, in the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL), according to study results presented at the 2017 International Workshop on Chronic Lymphocytic Leukemia. The impact of additional mutations, including TP53 and SF3B1, were also noted.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x